Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453532 | 0.93 | OPRD1 (0.66) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4932328 | 0.91 | OPRD1 (0.73) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5727063 | 0.90 | OPRD1 (0.69) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL6610713 | 0.89 | OPRD1 (0.71) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL14519201 | 0.88 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL14519199 | 0.88 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5000028 | 0.86 | OPRD1 (0.64) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4923207 | 0.86 | OPRD1 (0.67) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL14519200 | 0.86 | OPRD1 (0.60) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL5879331 | 0.85 | OPRD1 (0.75) | OPRD1OPRM1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205317-B2 | 4[piperidin-4-yliden-(3-carbamoylpheny)methyl]benzamide derivatives and their use for the treatment of pain spinal injuries or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2007-04-17 | — | — | US | disclosed |
| US-7205317-B2 | 4[piperidin-4-yliden-(3-carbamoylpheny)methyl]benzamide derivatives and their use for the treatment of pain spinal injuries or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2007-04-17 | — | — | US | disclosed |
| US-7205317-B2 | 4[piperidin-4-yliden-(3-carbamoylpheny)methyl]benzamide derivatives and their use for the treatment of pain spinal injuries or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2007-04-17 | — | — | US | disclosed |
| US-20050020629-A1 | 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain spinal injuries or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2005-01-27 | — | — | US | disclosed |
| EP-1440060-A1 | 4(PIPERIDIN-4-YLIDEN-(3-CARBAMOYLPHENYL)METHYL] BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, SPINAL INJURIES OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003029215-A1 | 4[PIPERIDIN-4-YLIDEN-(3-CARBAMOYLPHENYL)METHYL] BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, SPINAL INJURIES OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020629-A1 | 4[piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain spinal injuries or gastrointestinal disorders | BRS3, PTGER3, TRPA1 | OPRD1 29/4885OPRM1 9/4885OPRK1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.